[A21-101] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

Last updated 03.02.2022

Project no.:

Commission awarded on 01.08.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with multiple myeloma

Result of dossier assessment:
  • Patients who have already received 1 prior therapy with a proteasome inhibitor and lenalidomide and who were refractory to lenalidomide: added benefit not proven.
  • Patients who have already received ≥ 2 prior therapies containing lenalidomide and a proteasome inhibitor and who showed disease progression under or after the last therapy: added benefit not proven.

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2022-02-03 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form